Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial

Eur J Heart Fail. 2024 Apr;26(4):1093-1095. doi: 10.1002/ejhf.3240. Epub 2024 Apr 17.

¹ Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA.
² Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
³ CPC Clinical Research and University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
⁴ State University of New York Downstate School of Public Health, Brooklyn, NY, USA.
⁵ Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
⁶ Duke University School of Medicine, Durham, NC, USA.
⁷ Lexicon Pharmaceuticals, Inc, The Woodlands, TX, USA.
⁸ University of Michigan, Ann Arbor, MI, USA.
⁹ Université Paris-Cité, INSERMU1148 and AP-HP Hopital Bichat, Paris, France.
¹⁰ French Alliance for Cardiovascular Trials, Paris, France.

No abstract available

Publication types

Glycosides
(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol
Sodium-Glucose Transporter 2 Inhibitors
Hypoglycemic Agents